ScinoPharm Taiwan Ltd (1789) - Total Liabilities
Based on the latest financial reports, ScinoPharm Taiwan Ltd (1789) has total liabilities worth NT$1.55 Billion TWD (≈ $48.75 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore ScinoPharm Taiwan Ltd long-term investment allocation to see how much of total assets are deployed in long-term investments.
ScinoPharm Taiwan Ltd - Total Liabilities Trend (2007–2025)
This chart illustrates how ScinoPharm Taiwan Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see ScinoPharm Taiwan Ltd assets under control.
ScinoPharm Taiwan Ltd Competitors by Total Liabilities
The table below lists competitors of ScinoPharm Taiwan Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Tianjin Jieqiang Power Equipment Co
SHE:300875
|
China | CN¥368.91 Million |
|
KT Submarine Co. Ltd
KQ:060370
|
Korea | ₩79.71 Billion |
|
Apex Healthcare Bhd
KLSE:7090
|
Malaysia | RM219.04 Million |
|
Arko Corp
NASDAQ:ARKO
|
USA | $3.02 Billion |
|
Diamond Hill Investment Group Inc
NASDAQ:DHIL
|
USA | $83.97 Million |
|
Hubei Xiangyuan New Material Technology Inc.
SHE:300980
|
China | CN¥122.06 Million |
|
ICRA Limited
NSE:ICRA
|
India | Rs2.72 Billion |
Liability Composition Analysis (2007–2025)
This chart breaks down ScinoPharm Taiwan Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See net asset quality index of ScinoPharm Taiwan Ltd to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.55 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.15 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.13 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ScinoPharm Taiwan Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ScinoPharm Taiwan Ltd (2007–2025)
The table below shows the annual total liabilities of ScinoPharm Taiwan Ltd from 2007 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | NT$1.33 Billion ≈ $42.00 Million |
-5.92% |
| 2024-12-31 | NT$1.42 Billion ≈ $44.64 Million |
+4.40% |
| 2023-12-31 | NT$1.36 Billion ≈ $42.76 Million |
-7.12% |
| 2022-12-31 | NT$1.46 Billion ≈ $46.03 Million |
+23.81% |
| 2021-12-31 | NT$1.18 Billion ≈ $37.18 Million |
-10.42% |
| 2020-12-31 | NT$1.32 Billion ≈ $41.50 Million |
-6.88% |
| 2019-12-31 | NT$1.41 Billion ≈ $44.57 Million |
-30.12% |
| 2018-12-31 | NT$2.02 Billion ≈ $63.78 Million |
-11.38% |
| 2017-12-31 | NT$2.28 Billion ≈ $71.96 Million |
-10.61% |
| 2016-12-31 | NT$2.56 Billion ≈ $80.50 Million |
+8.06% |
| 2015-12-31 | NT$2.36 Billion ≈ $74.50 Million |
+18.73% |
| 2014-12-31 | NT$1.99 Billion ≈ $62.74 Million |
+8.18% |
| 2013-12-31 | NT$1.84 Billion ≈ $58.00 Million |
+45.06% |
| 2012-12-31 | NT$1.27 Billion ≈ $39.98 Million |
+37.83% |
| 2011-12-31 | NT$920.78 Million ≈ $29.01 Million |
+48.28% |
| 2010-12-31 | NT$620.97 Million ≈ $19.56 Million |
-54.07% |
| 2009-12-31 | NT$1.35 Billion ≈ $42.59 Million |
-41.76% |
| 2008-12-31 | NT$2.32 Billion ≈ $73.13 Million |
-25.21% |
| 2007-12-31 | NT$3.10 Billion ≈ $97.77 Million |
-- |
About ScinoPharm Taiwan Ltd
ScinoPharm Taiwan, Ltd., a pharmaceutical company, provides active pharmaceutical ingredient (API) development and manufacturing and injectable solutions in Taiwan, rest of Asia, Europe, and the Americas. It offers small molecules, peptide drugs, and steroids; drug products for anticancer, thromboembolic disorders, and osteoporosis; and contract analytical testing, sterile injectables contract ma… Read more